论文部分内容阅读
单胺氧化酶抑制剂(MAOI)用于治疗精神病和结核病时,能引起立位低血压,且毒性和副作用大,不宜作为降压药。在副作用较小的MAOI中,优降灵(Pargyline)则具有强的抑制单胺氧化酶作用和降压作用,是MAOI中第一个介绍到临床应用的降压药。关于优降灵的临床疗效报告不少,但药理研究材料较少。由于MAOI有一定毒性,为了保证病人安全,在临床试用优降灵以前,对共药理和毒性进行了一些研究。
Monoamine oxidase inhibitor (MAOI) for the treatment of mental illness and tuberculosis, can cause orthostatic hypotension, and toxicity and side effects, should not be used as antihypertensive drugs. Among MAOI with less side effects, Pargyline has the strong inhibitory effect on monoamine oxidase and antihypertensive effect, and is the first antihypertensive agent introduced into clinical application in MAOI. There are a lot of reports about the clinical efficacy of YOLP, but less material for pharmacological research. Due to the toxicity of MAOI, in order to ensure the safety of patients, some studies on the pharmacology and toxicity of ophthalmic drugs were conducted prior to the clinical trial of etharenol.